Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR101 Quality of Life Study in Peanut Allergy
NCT03703791Phase 3Terminated
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in peanut allergy comparing AR101 + SoC with Standard of Care (2 arms). Primary endpoint: Health-related Quality of Life at 18 months. Started Oct 2018; status: terminated.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03703791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703791.